Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Vexcel Has Agreed to Be Acquired by CoStar Group

    William Blair acted as the exclusive financial advisor to Vexcel Group, Inc. in connection with its pending sale to CoStar Group, Inc. (NASDAQ: CSGP).

    Read more

  • Beyond Borders: William Blair’s Active ETFs

    William Blair has spent decades investing outside the United States in developed and emerging markets, across both equity and fixed income. That similar approach is now available in an active ETF wrapper.

    Watch the video

  • William Blair Private Wealth Management Opens Dallas Office with New Advisory Team

    William Blair Private Wealth Management today announced the opening of an office in Dallas with the addition of a four-person wealth advisory team led by Ryan Berube and Allen Abney, managing directors and wealth advisors.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures